



FY23 Results (in conjunction with Appendix 4E)

*Accelerating Global
Impact*

23 August 2023

Healing. Redefined.



Disclaimer




This presentation has been prepared by PolyNovo Limited and is provided for general information purposes only. No party other than PolyNovo has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.


This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. PolyNovo Limited makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. PolyNovo and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, or contained in or derived from, or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of PolyNovo. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by PolyNovo or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.




NovoSorb BTM Publications




- Fully synthetic biodegradable polyurethane
- On formulation
- Facilitates reconstruction of a reinforced, vascularised dermal bed
- Sealing membrane physiologically closes the wound during integration
- Robust in the presence of infection
- Designed to minimise contracture over functionally important areas
- Generates a neodermis over exposed tendons and bones

- Full thickness burns and mixed-depth burns
- Trauma (degloving, crush injuries, scalp avulsion)
- Necrotising fasciitis
- Diabetic and Vascular wounds
- Skin cancer excision and oncology burns
- Meningococcal septicaemia
- Hidradenitis
- Scar revision
- Limb salvage and crush injuries
- Scalp avulsion
- Free flap donor sites


Total Employees



Customers (Hospitals)



Total Revenue A\$




➡ Team expansion

➡ New applications

ANZ ➡ U.S. ➡ UK/I ➡ Germany ➡ Canada ➡ Hong Kong ➡ India ➡ Spain ➡ France ➡ **China** ➡ **Japan**

Uniquely situated to drive Global impact

- **Genius Technology** for surgeons' simplicity and patient care
- **Surgeons engaged** in unprompted trials and publications
- **New applications**
- **Underserved market** : From 800m to 7.2B people
- **Growing team size**
- **Building a global footprint**
- **Capital Efficient Growth & Scaling**
- **Profit**




FY23 Financial Results


FY23 Financial Results



Total Revenue (\$m)



Regional Revenue (\$m) (Includes BARDA & Other Income)




Delivering on Revenue Growth

- Total Revenue \$66.5m up 58.8%
- Global NovoSorb sales \$59.6m up 58.3%
- U.S. NovoSorb sales \$46.1m up 44.6% (34.0% in local USD)
- Rest of world NovoSorb sales \$13.4m up 133.9% (includes new markets Canada, Hong Kong and India)
- Total BARDA Revenue \$5.7m up 49.2%

FY23 Financial Results



Revenue, Opex, NLAT (\$m) (excl. non-cash items)



Capital Efficient whilst Driving Growth

- Operating Expenses – exc. Non-cash items and interest +48.9%
- Investing capital raising funds to drive growth:
 - **Geographic expansion** - Entered Canada, Hong Kong and India
 - **New indications for NovoSorb** – Increased usage of NovoSorb across indications such as complex trauma, plastic & recon, and oncology
 - **New Products** – 510(k) clearance for NovoSorb MTX and first sales in U.S
 - **R&D Investment** – product pipeline development
 - **Clinical Trials** – build evidence to support product claims
 - **Capacity expansion** – commenced design of new co-located manufacturing facility, completed office expansion and increased headcount for year from 152 to 218

Net Loss after Tax (excl. non-cash items*)

- NLAT \$2.3m (excl. non-cash items)
- EBITDA \$2.5m (excl. non-cash items)
- **Cash on hand \$46.8m**

* Refer to reconciliation on page 10

FY23 Financial Results



(\$m)	FY23	FY22	Change %
Revenue (Excl. Interest)	65.7	41.9	56.8%
Expenses			
Changes in inventories & WIP	(4.4)	(2.2)	101.3%
Employee-related expenses *	(39.4)	(21.4)	84.1% *
R&D Costs	(7.4)	(5.7)	29.3%
Corp, administrative & overhead expenses	(17.4)	(10.4)	67.6%
Impairment Loss	0.0	(1.4)	-100.0%
Add Back: Depreciation included in Changes in inventories & WIP	0.2	0.2	
EBITDA	(2.8)	1.0	-391.9%
Depreciation & Amortisation	(2.0)	(1.6)	28.2%
Depreciation included in Changes in inventories & WIP	(0.2)	(0.2)	17.6%
EBIT	(5.1)	(0.8)	508.5%
Interest Income	0.9	0.0	
Interest Expense	(0.7)	(0.3)	
NET PROFIT/(LOSS) BEFORE TAX	(4.9)	(1.2)	328.6%
Income Tax Benefit / (Expense)	0.01	(0.04)	
NET PROFIT/(LOSS) AFTER TAX	(4.9)	(1.2)	312.9%
Add Back / Deduct Non-Cash Items:			
Share Based Payments	1.1	(3.5)	
Unrealised Forex	(0.8)	(0.5)	
Depreciation & Amortisation	2.0	1.6	
Depreciation & Amortisation in Changes in Inventories & WIP	0.2	0.2	
Impairment Loss	0.0	1.4	
NET PROFIT/(LOSS) AFTER TAX - EXCLUDING NON CASH ITEMS	(2.3)	(2.0)	16.0%

Highlights

- Total Revenue (incl. BARDA) **+58.8%**
- Employee related expenses **+50.9%**
- R&D spend **+29.3%** (product development, clinical trials)
- Corp, admin & overhead expenses **+67.6%** (new market entries, and infrastructure to drive and support growth)
- Operating expenses **+48.9%** (excl. non-cash items & interest)
- Net loss after tax **\$4.9m**
- **Net underlying loss after tax \$2.3m (Excl. non-cash items)**

* The underlying increase in employee related expenses is 50.9% rather than 84.1%. This is due to employee related expenses of \$21.4m in FY22 including the reversal of \$4.7m in share based payments

mal use only

